YWYow‐Ming Wang

Yow‐Ming Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yow‐Ming Wang has a total of 187 co-authors. Here are the top co-authors by number of shared publications:

  • Sarah J. Schrieber

    Science Review Staff Office of Therapeutic Biologics and Biosimilars Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA

    9 shared publications
  • David G. Strauss

    Division of Applied Regulatory Science Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration Silver Spring Maryland USA

    8 shared publications
  • Qin Sun

    Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, USA

    8 shared publications
  • Issam Zineh

    Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration Silver Spring Maryland USA

    6 shared publications
  • Jeffry Florian

    Division of Applied Regulatory Science Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration Silver Spring Maryland USA

    6 shared publications
  • Jie Wang

    Office of Clinical Pharmacology, Office of Translational Sciences, CDER Food and Drug Administration (FDA) Silver Spring Maryland USA

    6 shared publications

Latest Publications

  • Biosimilar Development Considerations for Therapeutic Proteins With Limited Systemic Exposure: A Landscape Analysis and Pathway Evaluation

    by Ting Wang, Jenny Zheng, Po‐Hung Hsieh, Anh‐Dung Le, Yow‐Ming Wang, Qin Sun

    Biosimilar development for therapeutic proteins (TPs) with limited systemic exposure presents distinct challenges, as the new paradigm based on comparative analytical assessments plus pharmacokinetic similarity without a comparative efficacy study (CES) is inapplicable. Of 19 TPs with limited systemic exposure, 15 are well‐characterized, of which 12 have at least one CES‐feasible indication. The remaining 3 may require alternative strategies, including pharmacodynamic (PD) biomarker approaches or optimized CES designs, underscoring the need for proactive regulatory engagement.

  • Perspective on Pharmacokinetic Comparability for Biologics Development

    by Fei Tang, Yifei Zhang, Mohamed Elmeliegy, Janki Mihir Desai, Yow‐Ming Wang, Zhenhua Xu

    Comparability assessment of biologics is essential to support manufacturing changes throughout drug development life cycle. Centering on pharmacokinetic comparability for biologics, this manuscript summarizes current and emerging insights drawing from a webinar hosted by the American Society for Clinical Pharmacology and Therapeutics Life Cycle Management Community. The common theme across industry and regulatory experiences is the use of risk‐based, hierarchical approaches to bridge pre‐ and post‐change products, ranging from foundational analytical comparability to clinical pharmacokinetic comparability studies.


  • FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease

    by Poonam R. Delvadia, Anantha Ram Nookala, Gopichand Gottipati, Sreedharan Sabarinath, Ramana S. Uppoor, Mehul U. Mehta, Xiulian Du, Yow‐Ming C. Wang, Milos Dokmanovic, Riley Myers, et al.

    The development and approval of biosimilars are imperative for improving patient access to safe and effective treatments. This article summarizes the regulatory approval for Tyruko, the first FDA‐approved biosimilar for natalizumab for the treatment of multiple sclerosis and Crohn's disease. Biosimilarity between the proposed biosimilar and the reference product was demonstrated through a comprehensive comparative assessment that included structural and functional characterization, pharmacokinetics (PK)/pharmacodynamics (PD) data, immunogenicity, and safety. The PD assessment incorporated a panel of biomarkers indicative of target engagement and downstream biological responses. The current case underscores the importance of the 351(k) pathway and highlights how the PD‐based approach, in conjunction with comparative analytical assessments and PK data, supported the approval of the biosimilar through a study design relying on fewer subjects and a shorter duration compared to an efficacy study.

  • Insights into PK ‐Based Bridging for Products Using a Common Autoinjector Platform: A Review of 16 Autoinjectors in 14 Biological License Applications

    by Zhe Li, Pei‐Rung Huang, Shiew Mei Huang, Yow‐Ming C. Wang

    An emerging proposal suggests that prior findings of pharmacokinetic comparability for one product could be applied to other therapeutic protein products that use the same autoinjector platform. We investigated 16 autoinjectors using one platform and found that (a) pharmacokinetic comparability outcomes varied and (b) these outcomes were not attributable to identified device performance parameters or product viscosity. Further investigations are necessary to support the proposed extrapolation across products sharing the same autoinjector platform.


  • The Need for Clinical Trial Dataset Specifications to Support Clinical Pharmacology Review of Immunogenicity

    by Sophie Shubow, Mohsen Rajabi Abhari, Anh Ta, Jeffry Florian, Peter Lee, Yow-Ming C Wang

    Assessment of product immunogenicity in clinical trials via characterization of the anti-drug antibody (ADA) response to the drug, is an important componen

  • Open Access

    Evaluating miRNA Sequencing and Integrative Proteomics for Identifying Plasma miRNAs as Potential Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics

    by Mai Mehanna, Lakshmi Manasa Chekka, Barry A. Rosenzweig, Deepti P. Samarth, Esraa G. Mohamed, Isaac Raplee, Catherine Sullenberger, Erica Decker, Sarah J. Schrieber, Yow‐Ming Wang, et al.

    We used miRNA sequencing to identify candidate plasma pharmacodynamic (PD) biomarkers of interferon beta‐1a (IFNβ‐1a) biologics and explored miRNA‐mRNA targeted protein relationships and networks to support identified miRNA candidates. Plasma samples from 36 healthy subjects from a placebo‐controlled randomized single‐dose clinical study with IFNβ‐1a and pegIFNβ‐1a were used. Mature miRNAs were measured using an in‐house miRNA‐seq workflow at baseline, at 9 timepoints over 6 days in the IFNβ‐1a group ( n = 11 [30 μg]), and at 11 timepoints over 13 days in the pegIFNβ‐1a group ( n = 11 [125 μg]) and placebo‐specific groups ( n = 6 each). A miRNA was only considered expressed if it had a read count ≥ 10 in more than 50% of the samples across all treatment groups. Linear mixed‐effects models ( lmer ) regressing miRNA changes with treatment, time, and their interaction were used to identify differentially expressed miRNAs, which were further prioritized based on the magnitude of response and biological relevance using in silico predicted miRNA‐protein targets and regulatory network analyses. Ten and 13 miRNAs were impacted by IFNβ‐1a and pegIFNβ‐1a, respectively ( lmer FDR‐corrected p value < 0.1), compared to placebo, of which miR‐223‐3p and miR‐21‐5p were prioritized as candidate PD biomarkers for both products. Systems‐level analysis of integrated proteomics data highlighted miRNAs' protein targets for both miR‐223‐3p and miR‐21‐5p that were linked to previously reported top proteomic response proteins and predicted regulatory networks including the IFN beta node. Using miRNA sequencing and linking candidates to predicted target proteins and regulatory networks, results suggest miR‐223‐3p and miR‐21‐5p as potential PD biomarkers of IFNβ‐1a biologics for further investigation.


  • Open Access

    Proteomic Identification of Plasma Biomarkers of Response to IL‐5 Inhibitor Biologics in Healthy Subjects

    by Lakshmi Manasa S. Chekka, Deepti P. Samarth, Kristina E. Howard, Yan Guo, Esraa G. Mohamed, Erica Decker, William Wheeler, Joel Wommack, Joseph Gogain, Jennifer Deering, et al.

    Proteomics can identify pharmacodynamic (PD) biomarkers by detecting protein changes in response to drug treatment, providing insights into drug mechanism and biological effects. In this study, we profiled over 7000 plasma proteins to identify potential PD biomarkers for the interleukin‐5 (IL‐5) inhibitors mepolizumab and reslizumab, which are approved for treating eosinophilic asthma. We used longitudinal plasma samples from healthy participants treated with a single dose of mepolizumab ( n = 8, 24 mg) or reslizumab ( n = 8, 0.8 mg/kg), or placebo ( n = 8) to identify differentially expressed proteins. We then characterized PD biomarker candidates by their magnitude of response, area under the effect curve (AUEC), dose–response, variability, and replication of response at a lower dose for mepolizumab ( n = 8, 12 mg) or reslizumab ( n = 8, 0.4 mg/kg) compared to placebo. Eosinophil major basic protein (EMBP) and proteoglycan‐3 (PRG3) were differentially expressed in response to mepolizumab and reslizumab, respectively, achieving Bonferroni‐adjusted statistical significance ( p ‐value < 6.86E‐06) and nominal significance ( p ‐value < 5.0E‐05) with the other IL‐5 inhibitor. EMBP showed a > 20% fold change difference with mepolizumab (24 mg) versus placebo at peak time, and PRG3 demonstrated a > 20% fold change with reslizumab (0.8 mg/kg) versus placebo at peak time. Both proteins had significant AUEC with both drug doses, with EMBP AUEC only significant (absolute AUEC high > low dose) at the higher mepolizumab dose. Both biomarkers showed dose–response trends and comparable variability to placebo. Our study identified EMBP and PRG3 as promising plasma PD biomarkers for IL‐5 inhibitors, warranting further validation for early phase trials and biosimilar development programs.


  • Clinical Pharmacology Characterization of Bispecific T‐Cell Engagers: A Summary Based on FDA Approvals

    by Ting Wang, Yow‐Ming Wang, Qin Sun

    Bispecific T‐cell engagers (Bi‐TCEs) have demonstrated clinical efficacy and safety, with 7 approved for hematological cancers and 2 approved for solid tumors by the US Food and Drug Administration (FDA) as of May 2025. Its intricate mechanism of action through the formation of a trimer involving Bi‐TCE, T cell, and tumor cell presents challenges to clinical development requiring special strategies for multiple disciplines. This review summarizes key clinical pharmacology characterizations of these 9 FDA‐approved Bi‐TCEs to understand the current practice and to identify potential knowledge gaps. The topics covered include dosing strategies, general clinical pharmacology evaluations, and cytokine‐related drug–drug interaction (DDI) assessment. The dosing strategy part discusses the criteria for step‐up dose and full treatment dose selection, the potential for further optimization of dose regimen in later cycles, and the analyses supporting the restarting strategy after dosage delay. The section on general clinical pharmacology evaluations summarizes pharmacokinetic (PK) property and its impact on dosing strategy, PK in specific populations (e.g., organ impairment, pediatrics), pharmacodynamics property, and immunogenicity information. The cytokine‐related DDI part discusses cytokine profiles, risk mitigation strategy, and physiologically based PK (PBPK) models and their limitations. Finally, future perspectives are provided regarding efficient dose selection, PBPK modeling application, and Bi‐TCEs for solid tumors and non‐oncology indications.


  • Open Access

    Characterization of Proteomic Pharmacodynamic Biomarkers of IFNβ‐1a Biologics to Inform Potential Utility in Biosimilar Development

    by Lakshmi Manasa S. Chekka, Deepti P. Samarth, Yan Guo, Esraa G. Mohamed, Erica Decker, Murali K. Matta, Qin Sun, William Wheeler, Carlos Sanabria, Joel Wommack, et al.

    Pharmacodynamic (PD) biomarkers can support biosimilarity assessment, potentially reducing the need for comparative clinical efficacy studies. This study aimed to characterize previously identified proteomic PD biomarker candidates for Interferon beta‐1a (IFNβ‐1a, n = 248) and pegylated IFNβ‐1a (pegIFNβ‐1a, n = 528) biologics at therapeutic doses, to further evaluate the utility of proteomics in biosimilar development. Here, we reproduced the results at lower doses and characterized PD responses across multiple doses using criteria for justifying PD biomarker use in biosimilar development. We analyzed candidate proteins from longitudinal proteomics data (SomaScan™ Assay v4.1) from 48 healthy subjects administered intermediate or low doses of IFNβ‐1a (15, 7.5 μg) or pegIFNβ‐1a (62.5, 31.25 μg) in an FDA‐sponsored study, alongside previously published therapeutic dose and placebo data. EDTA plasma samples were collected at 0, 0.125, 0.33, 0.67, 1.33, 2, 3, 4, 5, 6 days and at 9, 13 days additionally for pegIFNβ‐1a. Prioritization criteria included significant differential expression at the intermediate dose vs. placebo, ≥20% response difference from placebo, significant baseline‐adjusted area under the effect curve (AUEC) and a monotonic dose–response relationship across all doses. Among the candidates, 165 and 323 were differentially expressed at intermediate doses of IFNβ‐1a and pegIFNβ‐1a respectively. Nine PD biomarkers, including C‐X‐C motif chemokine 11 (I‐TAC), Lymphocyte activation gene 3 protein (LAG3), and Granulins (GRN), were prioritized as common to both biologics. Most candidates followed the Emax dose–response model. I‐TAC showed the strongest response, and LAG‐3 showed the least variability in AUEC. Our study identified several suitable plasma PD biomarkers for IFNβ‐1a and pegIFNβ‐1a biologics with potential utility in biosimilar development programs.